Currency In USD
| Previous Close | 0.36 |
| Open | 0.36 |
| Day High | 0.36 |
| Day Low | 0.36 |
| 52-Week High | 2.26 |
| 52-Week Low | 0.29 |
| Volume | 283,774 |
| Average Volume | 404,925 |
| Market Cap | 8.21M |
| PE | -0.17 |
| EPS | -2.04 |
| Moving Average 50 Days | 0.36 |
| Moving Average 200 Days | 0.41 |
| Change | 0 |
Data not available
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
GlobeNewswire Inc.
May 08, 2025 10:00 PM GMT
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with sol
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
GlobeNewswire Inc.
Feb 04, 2025 2:00 PM GMT
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources,
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
GlobeNewswire Inc.
Nov 05, 2024 2:01 PM GMT
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluat